eFFECTOR Therapeutics (eFFECTOR Therapeutics) Pre-Tax Income : $-35.81 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. eFFECTOR Therapeutics's pretax income for the three months ended in Dec. 2023 was $-9.13 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.81 Mil. eFFECTOR Therapeutics's pretax margin was %.

During the past 4 years, eFFECTOR Therapeutics's highest Pretax Margin was 34.67%. The lowest was 34.67%. And the median was 34.67%.

eFFECTOR Therapeutics Pre-Tax Income Historical Data

The historical data trend for eFFECTOR Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Pre-Tax Income Chart

eFFECTOR Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

14.56

15.80

-22.67

-35.81

eFFECTOR Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial									-9.26	-10.01	-8.36	-8.30	-9.13

Competitive Comparison of eFFECTOR Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, eFFECTOR Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

eFFECTOR Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Pre-Tax Income falls into.

eFFECTOR Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

eFFECTOR Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-33.844	+	-0.02	+	-2.919	+	0.972	+	0
	=	-35.81

eFFECTOR Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-8.598	+	0.003	+	-0.758	+	0.223	+	0
	=	-9.13

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.81 Mil.

eFFECTOR Therapeutics (NAS:EFTR) Pre-Tax Income Explanation

eFFECTOR Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-9.13	/	0
	=	%

During the past 4 years, eFFECTOR Therapeutics's highest Pretax Margin was 34.67%. The lowest was 34.67%. And the median was 34.67%.

eFFECTOR Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

eFFECTOR Therapeutics (eFFECTOR Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (NAS:EFTR) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

LWK:Germany LWK:Germany

Address

142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075

Website

https://www.effector.com

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Executives

Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich	director, 10 percent owner, officer: Chief Executive Officer	499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi	officer: Chief Business Officer	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner	officer: Chief Medical Officer	C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc	10 percent owner	2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc	10 percent owner	1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc	10 percent owner	C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c.	10 percent owner	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr.	director, 10 percent owner	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland	director, officer: President and Chief Executive	9050 CAMINO SANTA FE, SAN DIEGO CA 92121